$BIIB Headlines Goldman's biotech downgrade and
Post# of 72747
Posted On: 01/08/2014 2:52:15 PM
$BIIB Headlines
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Charting a bullish year-end backdrop 12:29 p.m. Dec. 17, 2013 - Michael Ashbaugh
Charting a bullish year-end backdrop 12:03 p.m. Dec. 17, 2013 - Michael Ashbaugh
Get your portfolio to turn the corner 2:33 p.m. Dec. 10, 2013 - The Trading Deck
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Growth stock players should reduce expectations 1:19 p.m. Nov. 26, 2013 - The Trading Deck
DaVita, Fresenius gain; energy firms slip 4:56 p.m. Nov. 25, 2013 - Ben Eisen
Stocks gain for 7th week; S&P ends above 1,800 4:24 p.m. Nov. 22, 2013 - Polya Lesova
Biogen Idec jumps; Intel, Ross Stores slide 4:23 p.m. Nov. 22, 2013 - Saumya Vaishampayan
Biogen surges 13%, best on S&P 500 9:33 a.m. Nov. 22, 2013 - Laura Mandaro
The Four Horsemen send a message 12:47 p.m. Nov. 13, 2013 - The Trading Deck
Biogen shares hit new high as Tecfidera sales crush estimates 9:50 a.m. Oct. 28, 2013 - Russ Britt
Apple is Monday’s stock to watch as results loom 7:22 a.m. Oct. 28, 2013 - Sue Chang
Biogen Idec profit up 22% on Tecfidera sales boost 7:09 a.m. Oct. 28, 2013 - MarketWatch.com
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
Baxter profit falls on costs of Gambro purchase 9:28 a.m. Oct. 17, 2013 - MarketWatch.com
Tesla stuck in reverse, Herbalife loses momentum 3:35 p.m. Oct. 3, 2013 - Sue Chang
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Charting the technicals ahead of the Fed 10:52 a.m. Sept. 18, 2013 - Michael Ashbaugh
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock 1:50 p.m. Today - TheStreet.com
5 Stocks Improving Performance Of The Health Care Sector 12:03 p.m. Today - TheStreet.com
Nomura starts coverage on multiple biotechs 10:46 a.m. Today - Seeking Alpha
Benzinga's Top Initiations 7:05 a.m. Today - benzinga.com
Notice of Allowance Received by Alkermes - Analyst Blog 4:21 p.m. Jan. 7, 2014 - Zacks.com
Is the Biotech Boom Over? 10:58 a.m. Jan. 7, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Profiting From Down Days 8:20 p.m. Jan. 6, 2014 - TheStreet.com
Royalty Pharm Acquires Additional Interest in Biogen Drug 9:07 a.m. Jan. 6, 2014 - WSJ.com
Citi's top biotech picks include Biogen, Gilead, and Celgene 8:33 a.m. Jan. 6, 2014 - Seeking Alpha
Perrigo Maintained at Neutral - Analyst Blog 5:35 p.m. Jan. 3, 2014 - Zacks.com
Biogen Leverages Strength In MS Treatments 5:35 p.m. Jan. 3, 2014 - Investors Business Daily
5 Stocks Pulling The Drugs Industry Downward 12:03 p.m. Jan. 3, 2014 - TheStreet.com
Q4 Tecfidera numbers tracking ahead of estimates: Wells Fargo 11:30 a.m. Jan. 3, 2014 - Seeking Alpha
The Top Five Drug Launches Of 2013 12:42 p.m. Dec. 31, 2013 - Investors Business Daily
Health Care Is The Leading Sector In the Big Cap 20 5:04 p.m. Dec. 30, 2013 - Investors Business Daily
Sanofi Appeals MS Drug Rejection 12:20 p.m. Dec. 30, 2013 - WSJ.com
Lemtrada news marginally positive for Biogen: Wells Fargo 9:22 a.m. Dec. 30, 2013 - Seeking Alpha
Bargain-Bin Stocks Take Lead in Rally 5:50 p.m. Dec. 29, 2013 - WSJ.com
Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard 5:01 p.m. Dec. 27, 2013 - TheStreet.com
3 Stocks Dragging In The Drugs Industry 12:03 p.m. Dec. 27, 2013 - TheStreet.com
Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference 5:29 p.m. Jan. 7, 2014 - BusinessWire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Stock Price Movement, Financial Reports Schedules, Conference Participation, Leadership Changes, and Donation - Research Report on Biogen Idec, Forest, PerkinElmer, Techne, and USANA 8:00 a.m. Jan. 7, 2014 - PR Newswire
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 4:00 p.m. Jan. 2, 2014 - BusinessWire
Commercialization Agreements, Acquisition Updates, Conference Calls Schedules, Stock Price Updates and Clinical Study Data - Research Report on Biogen Idec, Covidien, Vertex, Endo, and Momenta Pharma 8:00 a.m. Dec. 31, 2013 - PR Newswire
Commercial Agreements, Stock Price Updates, Regulatory Approvals, Patent Litigation Settlements, and New Health Plan Strategies - Research Report on Biogen, Express Scripts, GSK, Actavis, and Aetna 8:00 a.m. Dec. 23, 2013 - PR Newswire
WCG Hires Adam Cohen, Digital Thought Leader, to Strengthen Technology Practice 8:00 a.m. Dec. 17, 2013 - BusinessWire
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe 2:00 a.m. Dec. 17, 2013 - BusinessWire
Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America 8:00 a.m. Dec. 13, 2013 - PR Newswire
RBCC and Therakine Initiate Phase II of Drug Delivery Development 5:00 a.m. Dec. 12, 2013 - BusinessWire
Biogen Idec Foundation in Collaboration with Cambridge Community Foundation Awards Grants in Science Education 9:00 a.m. Dec. 11, 2013 - BusinessWire
Swedish Orphan Biovitrum AB (publ): New phase 3 data confirm long-lasting characteristics of rFIXFc and rFVIIIFc across multiple haemophilia populations 11:31 a.m. Dec. 9, 2013 - Thomson Reuters ONE
New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX(TM) and ELOCTATE(TM) Across Multiple Hemophilia Populations 11:30 a.m. Dec. 9, 2013 - BusinessWire
Proteostasis Therapeutics Announces Collaboration with Biogen Idec for Research, Development and Commercialization of Therapies for Neurodegenerative Diseases 8:30 a.m. Dec. 9, 2013 - BusinessWire
Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care Relationship and Stock Price Updates - Research Report on Forest Laboratories, Biogen, Bristol-Myers, Express Scripts, and Aetna 8:00 a.m. Dec. 5, 2013 - PR Newswire
The New England Journal of Medicine publishes pivotal data demonstrating prophylactic infusions of Alprolix(TM) effectively controlled bleeding in haemophilia B patients 2:01 a.m. Dec. 5, 2013 - Thomson Reuters ONE
The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX(TM) Effectively Controlled Bleeding in Hemophilia B Patients 5:00 p.m. Dec. 4, 2013 - BusinessWire
Sobi's partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting 7:31 a.m. Dec. 3, 2013 - Thomson Reuters ONE
Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting 7:30 a.m. Dec. 3, 2013 - BusinessWire
Sobi's partner Biogen Idec receives notification from FDA of PDUFA date extension for ALPROLIX(TM) 7:33 a.m. Dec. 2, 2013 - GlobeNewswire
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Charting a bullish year-end backdrop 12:29 p.m. Dec. 17, 2013 - Michael Ashbaugh
Charting a bullish year-end backdrop 12:03 p.m. Dec. 17, 2013 - Michael Ashbaugh
Get your portfolio to turn the corner 2:33 p.m. Dec. 10, 2013 - The Trading Deck
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Growth stock players should reduce expectations 1:19 p.m. Nov. 26, 2013 - The Trading Deck
DaVita, Fresenius gain; energy firms slip 4:56 p.m. Nov. 25, 2013 - Ben Eisen
Stocks gain for 7th week; S&P ends above 1,800 4:24 p.m. Nov. 22, 2013 - Polya Lesova
Biogen Idec jumps; Intel, Ross Stores slide 4:23 p.m. Nov. 22, 2013 - Saumya Vaishampayan
Biogen surges 13%, best on S&P 500 9:33 a.m. Nov. 22, 2013 - Laura Mandaro
The Four Horsemen send a message 12:47 p.m. Nov. 13, 2013 - The Trading Deck
Biogen shares hit new high as Tecfidera sales crush estimates 9:50 a.m. Oct. 28, 2013 - Russ Britt
Apple is Monday’s stock to watch as results loom 7:22 a.m. Oct. 28, 2013 - Sue Chang
Biogen Idec profit up 22% on Tecfidera sales boost 7:09 a.m. Oct. 28, 2013 - MarketWatch.com
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
Baxter profit falls on costs of Gambro purchase 9:28 a.m. Oct. 17, 2013 - MarketWatch.com
Tesla stuck in reverse, Herbalife loses momentum 3:35 p.m. Oct. 3, 2013 - Sue Chang
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Charting the technicals ahead of the Fed 10:52 a.m. Sept. 18, 2013 - Michael Ashbaugh
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock 1:50 p.m. Today - TheStreet.com
5 Stocks Improving Performance Of The Health Care Sector 12:03 p.m. Today - TheStreet.com
Nomura starts coverage on multiple biotechs 10:46 a.m. Today - Seeking Alpha
Benzinga's Top Initiations 7:05 a.m. Today - benzinga.com
Notice of Allowance Received by Alkermes - Analyst Blog 4:21 p.m. Jan. 7, 2014 - Zacks.com
Is the Biotech Boom Over? 10:58 a.m. Jan. 7, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Profiting From Down Days 8:20 p.m. Jan. 6, 2014 - TheStreet.com
Royalty Pharm Acquires Additional Interest in Biogen Drug 9:07 a.m. Jan. 6, 2014 - WSJ.com
Citi's top biotech picks include Biogen, Gilead, and Celgene 8:33 a.m. Jan. 6, 2014 - Seeking Alpha
Perrigo Maintained at Neutral - Analyst Blog 5:35 p.m. Jan. 3, 2014 - Zacks.com
Biogen Leverages Strength In MS Treatments 5:35 p.m. Jan. 3, 2014 - Investors Business Daily
5 Stocks Pulling The Drugs Industry Downward 12:03 p.m. Jan. 3, 2014 - TheStreet.com
Q4 Tecfidera numbers tracking ahead of estimates: Wells Fargo 11:30 a.m. Jan. 3, 2014 - Seeking Alpha
The Top Five Drug Launches Of 2013 12:42 p.m. Dec. 31, 2013 - Investors Business Daily
Health Care Is The Leading Sector In the Big Cap 20 5:04 p.m. Dec. 30, 2013 - Investors Business Daily
Sanofi Appeals MS Drug Rejection 12:20 p.m. Dec. 30, 2013 - WSJ.com
Lemtrada news marginally positive for Biogen: Wells Fargo 9:22 a.m. Dec. 30, 2013 - Seeking Alpha
Bargain-Bin Stocks Take Lead in Rally 5:50 p.m. Dec. 29, 2013 - WSJ.com
Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard 5:01 p.m. Dec. 27, 2013 - TheStreet.com
3 Stocks Dragging In The Drugs Industry 12:03 p.m. Dec. 27, 2013 - TheStreet.com
Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference 5:29 p.m. Jan. 7, 2014 - BusinessWire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Stock Price Movement, Financial Reports Schedules, Conference Participation, Leadership Changes, and Donation - Research Report on Biogen Idec, Forest, PerkinElmer, Techne, and USANA 8:00 a.m. Jan. 7, 2014 - PR Newswire
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 4:00 p.m. Jan. 2, 2014 - BusinessWire
Commercialization Agreements, Acquisition Updates, Conference Calls Schedules, Stock Price Updates and Clinical Study Data - Research Report on Biogen Idec, Covidien, Vertex, Endo, and Momenta Pharma 8:00 a.m. Dec. 31, 2013 - PR Newswire
Commercial Agreements, Stock Price Updates, Regulatory Approvals, Patent Litigation Settlements, and New Health Plan Strategies - Research Report on Biogen, Express Scripts, GSK, Actavis, and Aetna 8:00 a.m. Dec. 23, 2013 - PR Newswire
WCG Hires Adam Cohen, Digital Thought Leader, to Strengthen Technology Practice 8:00 a.m. Dec. 17, 2013 - BusinessWire
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe 2:00 a.m. Dec. 17, 2013 - BusinessWire
Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America 8:00 a.m. Dec. 13, 2013 - PR Newswire
RBCC and Therakine Initiate Phase II of Drug Delivery Development 5:00 a.m. Dec. 12, 2013 - BusinessWire
Biogen Idec Foundation in Collaboration with Cambridge Community Foundation Awards Grants in Science Education 9:00 a.m. Dec. 11, 2013 - BusinessWire
Swedish Orphan Biovitrum AB (publ): New phase 3 data confirm long-lasting characteristics of rFIXFc and rFVIIIFc across multiple haemophilia populations 11:31 a.m. Dec. 9, 2013 - Thomson Reuters ONE
New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX(TM) and ELOCTATE(TM) Across Multiple Hemophilia Populations 11:30 a.m. Dec. 9, 2013 - BusinessWire
Proteostasis Therapeutics Announces Collaboration with Biogen Idec for Research, Development and Commercialization of Therapies for Neurodegenerative Diseases 8:30 a.m. Dec. 9, 2013 - BusinessWire
Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care Relationship and Stock Price Updates - Research Report on Forest Laboratories, Biogen, Bristol-Myers, Express Scripts, and Aetna 8:00 a.m. Dec. 5, 2013 - PR Newswire
The New England Journal of Medicine publishes pivotal data demonstrating prophylactic infusions of Alprolix(TM) effectively controlled bleeding in haemophilia B patients 2:01 a.m. Dec. 5, 2013 - Thomson Reuters ONE
The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX(TM) Effectively Controlled Bleeding in Hemophilia B Patients 5:00 p.m. Dec. 4, 2013 - BusinessWire
Sobi's partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting 7:31 a.m. Dec. 3, 2013 - Thomson Reuters ONE
Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting 7:30 a.m. Dec. 3, 2013 - BusinessWire
Sobi's partner Biogen Idec receives notification from FDA of PDUFA date extension for ALPROLIX(TM) 7:33 a.m. Dec. 2, 2013 - GlobeNewswire
(0)
(0)